Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis

Clinical Rheumatology

Volumn 30, Issue 2, 2011, Pages 231-237

  Hasegawa, Minoru ^a   Fujimoto, Manabu ^a   Matsushita, Takashi ^a   Hamaguchi, Yasuhito ^a   Takehara, Kazuhiko ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemokines; Cytokines; Marker; MCP 1; Scleroderma

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPANESE; MALE; PRIORITY JOURNAL; PROGNOSIS; SCLERODERMA; SCORING SYSTEM; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

ADULT; AGED; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 79954450466     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1610-4     Document Type: Article

References (30)

1. Denton CP, Black CM (2005) Targeted therapy comes of age in scleroderma. Trends Immunol 26:596-602. (Pubitemid 41726447)
2. Charles C, Clements P, Furst DE (2006) Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367:1683-1691. (Pubitemid 43728250)
3. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557-567. (Pubitemid 46348510)
4. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27:645-653. (Pubitemid 14089474)
5. Gruschwitz M, Sepp N, Kofler H, Wick G (1991) Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology 182:234-255.
6. Hasegawa M, Sato S (2008) The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci 13:3637-3647. (Pubitemid 351594648)
7. Atamas SP, White B (2008) The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 15:772-777. (Pubitemid 38156306)
8. Yamamoto T (2008) Pathogenic role of CCL2/MCP-1 in scleroderma. Front Biosci 13:2686-2695. (Pubitemid 351599712)
9. Distler JH, Akhmetshina A, Schett G, Distler O (2009) Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. BRheumatology (Oxford) 48:98-103.
10. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319-12324. (Pubitemid 37271558)
11. Varga J, Korn JH (2004) Pathogenesis: emphasis on human data. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Philadelphia, pp 63-98.
12. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437-2444.
13. Medsger TA Jr (2004) Classification, purpose. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Philadelphia, pp 17-28.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590.
15. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202-205. (Pubitemid 18073738)
16. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892-1896. (Pubitemid 24031593)
17. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203. (Pubitemid 18088039)
18. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391-394. (Pubitemid 24093631)
19. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ (2000) Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411. (Pubitemid 30164344)
20. Gharaee-Kermani M, Denholm EM, Phan SH (1996) Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 271:17779-17784. (Pubitemid 26250752)
21. Hasegawa M, Sato S, Takehara K (1999) Augmented production of chemokines (MCP-1, MIP-1a, andMIP-1b) in patients with systemic sclerosis:MCP-1 andMIP-1amay be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117:159-165.
22. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL (2001) Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 44:1382-1386. (Pubitemid 32537537)
23. Yamamoto T, Eckes B, Krieg T (2001) High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 31:2936-2941. (Pubitemid 32994545)
24. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, LandthalerMet al (2001) Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44:2665-2678. (Pubitemid 33049344)
25. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M et al (2008) CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatol Oxf 47:45- 49. (Pubitemid 350286260)
26. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S (2004) Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 35:43-51. (Pubitemid 38759740)
27. Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672-676. (Pubitemid 15232881)
28. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM (1995) Human Mig chemokine: biochemical and functional characterization. J Exp Med 182:1301-1314.
29. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76:779-786. (Pubitemid 14142675)
30. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487-495. (Pubitemid 351239185)